- Home
- COOT vs TNXP Comparison
COOT vs TNXP Comparison
Compare COOT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COOT
- TNXP
- Stock Information
- Founded
- COOT 2020
- TNXP 2007
- Country
- COOT Australia
- TNXP United States
- Employees
- COOT N/A
- TNXP N/A
- Industry
- COOT
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- COOT
- TNXP Health Care
- Exchange
- COOT NYSE
- TNXP Nasdaq
- Market Cap
- COOT 20.4M
- TNXP 19.5M
- IPO Year
- COOT N/A
- TNXP N/A
- Fundamental
- Price
- COOT $0.92
- TNXP $0.13
- Analyst Decision
- COOT
- TNXP Strong Buy
- Analyst Count
- COOT 0
- TNXP 2
- Target Price
- COOT N/A
- TNXP $53.50
- AVG Volume (30 Days)
- COOT 144.8K
- TNXP 13.8M
- Earning Date
- COOT 01-01-0001
- TNXP 11-12-2024
- Dividend Yield
- COOT N/A
- TNXP N/A
- EPS Growth
- COOT N/A
- TNXP N/A
- EPS
- COOT N/A
- TNXP N/A
- Revenue
- COOT N/A
- TNXP $11,291,000.00
- Revenue This Year
- COOT N/A
- TNXP $62.53
- Revenue Next Year
- COOT N/A
- TNXP $26.17
- P/E Ratio
- COOT N/A
- TNXP N/A
- Revenue Growth
- COOT N/A
- TNXP 183.05
- 52 Week Low
- COOT $0.61
- TNXP $0.12
- 52 Week High
- COOT $11.96
- TNXP $22.08
- Technical
- Relative Strength Index (RSI)
- COOT 60.88
- TNXP 33.87
- Support Level
- COOT $0.61
- TNXP $0.13
- Resistance Level
- COOT $0.77
- TNXP $0.15
- Average True Range (ATR)
- COOT 0.10
- TNXP 0.01
- MACD
- COOT 0.02
- TNXP 0.00
- Stochastic Oscillator
- COOT 96.83
- TNXP 4.86
About COOT AUSTRALIAN OILSEEDS HOLDINGS LTD
Australian Oilseeds Holdings Ltd through its subsidiaries, is focused on the manufacture and sale of chemical-free, non-GMO, sustainable edible oils and products derived from oilseeds. The company believes that transitioning from a fossil fuel economy to a renewable and chemical-free economy is the solution to many health problems the world is facing presently.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.